Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

This study is testing whether adding sintilimab (an immunotherapy drug) to standard chemotherapy (AVD regimen) improves treatment outcomes for children and teenagers with low- to moderate-risk classical Hodgkin lymphoma — a cancer of the lymph nodes. **You may be eligible if...** - You are between 1 and 18 years old - You have a newly diagnosed classical Hodgkin lymphoma confirmed by biopsy - Your disease is classified as low-risk (stage IA or IIA without a large chest mass) or moderate-risk (stage I/II with a large chest mass, or stage IIIA) - You have not received any prior treatment for this cancer **You may NOT be eligible if...** - You have high-risk or advanced-stage Hodgkin lymphoma (stage IIIB or IV) - You have received prior cancer treatment - You have significant heart, liver, kidney, or immune system problems - You have an active infection or autoimmune condition Talk to your doctor to see if this trial is right for you.